Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Gains from Sales and Divestitures (2020 - 2025)

Adma Biologics (ADMA) has disclosed Gains from Sales and Divestitures for 6 consecutive years, with $1.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Sales and Divestitures fell 0.61% year-over-year to $1.9 million, compared with a TTM value of $1.9 million through Dec 2025, down 0.61%, and an annual FY2025 reading of $1.9 million, down 0.61% over the prior year.
  • Gains from Sales and Divestitures was $1.9 million for Q4 2025 at Adma Biologics, up from $1.8 million in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $2.7 million in Q4 2022 and bottomed at $87750.0 in Q2 2021.
  • Average Gains from Sales and Divestitures over 5 years is $1.1 million, with a median of $1.2 million recorded in 2023.
  • The sharpest move saw Gains from Sales and Divestitures surged 2840.61% in 2022, then tumbled 56.02% in 2023.
  • Year by year, Gains from Sales and Divestitures stood at $92750.0 in 2021, then soared by 2840.61% to $2.7 million in 2022, then crashed by 56.02% to $1.2 million in 2023, then soared by 57.28% to $1.9 million in 2024, then decreased by 0.61% to $1.9 million in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for ADMA at $1.9 million in Q4 2025, $1.8 million in Q3 2025, and $1.6 million in Q2 2025.